Sumary of A review of natural immunity, vaccines, and variants in SARS-CoV-2 reinfection:
- The coronavirus disease 2019 (COVID-19) pandemic is an ongoing global health issue caused by the novel coronavirus severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2).
- Many rigorous studies have been conducted to understand the pathogenesis and transmissibility of SARS-CoV-2. Despite all these efforts, many areas are still unexplored, such as SARS-CoV-2 reinfection and reactivation.
- Literature review on COVID-19 reinfection In a literature review article published in the Journal of Community Hospital Internal Medicine Perspectives, authors from the US performed a thorough investigation of previous studies and case reports of SARS-CoV-2 reinfection.
- This review discusses the role of natural immunity, vaccines, and SARS-CoV-2 variants in reinfection.
- In addition, some studies define reinfection as having negative tests in between two positive SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) tests besides the genotypic variation.
- This review considered reinfection in individuals tested for SARS-CoV-2 using RT-PCR during the first pandemic wave before June 2020 and followed the study group from September to December 2020 to evaluate SARS-CoV-2 contraction.
- discussed the first case of reinfection in the US in a 25-year-old man whose two nasopharyngeal RT-PCR reports within the gap of 2 months revealed genetically different variants of SARS-CoV-2. Another study by Hall et al.
- found that the previous history of SARS-CoV-2 infection can lower the risk of reinfection by 83%, and its protective effect may last up to 5 months.